Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer
Read More
Monthly Archives: November 2015
Recent News
- Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018: Promising MP0250 clinical data in oncology and positive abicipar phase 3 efficacy data presented
- Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
- Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company
- Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm
- Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018
Archives
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- November 2017
- October 2017
- September 2017
- August 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- November 2016
- October 2016
- September 2016
- July 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- May 2015
- March 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- December 2013
- January 2013
- November 2012
- August 2012
- December 2011
- May 2011
- April 2011
- September 2010
- June 2010
- April 2010
- December 2009
- May 2009
- January 2008
- November 2007
- August 2007
- April 2007
- February 2007
- November 2006
- July 2006
- February 2005
